PSTX Insider Trading Activity and SEC Form 4 Filings
PSTX insider trading summary
No open-market insider purchases or sales of Poseida Therapeutics, Inc. (PSTX) have been reported on SEC Form 4 in the past 12 months.
Latest PSTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 10, 2024 | Mark J Gergen | Executive Chairman | Sell | $284K (30,000 @ $9.46) |
| Nov 26, 2024 | Mark J Gergen | Executive Chairman | Sell | $278K (30,000 @ $9.27) |
| Aug 8, 2022 | Eric Ostertag | Executive Chairman | Buy | $500K (142,857 @ $3.50) |
| Aug 8, 2022 | Malin Life Sciences Holdings Ltd | 10% Owner | Buy | $7.5M (2,150,000 @ $3.50) |
| Aug 3, 2022 | Eric Ostertag | Executive Chairman | Sell | $593K (160,696 @ $3.69) |
| Mar 16, 2022 | Kerry D. Ingalls | Chief Operating Officer | Buy | $12K (3,000 @ $3.98) |
| Dec 6, 2021 | Malin Life Sciences Holdings Ltd | 10% Owner | Buy | $13K (1,828 @ $6.90) |
| Dec 2, 2021 | Malin Life Sciences Holdings Ltd | 10% Owner | Buy | $30K (4,296 @ $6.88) |
| Dec 1, 2021 | Malin Life Sciences Holdings Ltd | 10% Owner | Buy | $126K (18,365 @ $6.85) |
| Nov 30, 2021 | Malin Life Sciences Holdings Ltd | 10% Owner | Buy | $196K (28,592 @ $6.85) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.